PPAR : a dagger in the heart of the metabolic syndrome
Open accessThe DOI matches its Crossref record; 97 of the 100 references it cites were found in a registry or an index.
Abstract
Obesity is a growing threat to global health by virtue of its association with insulin resistance, glucose intolerance, hypertension, and dyslipidemia, collectively known as the metabolic syndrome or syndrome X. The nuclear receptors PPARalpha and PPARgamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively, and drugs that modulate these receptors are currently in clinical use. More recent work on the less-described PPAR isotype PPARdelta has uncovered a dual benefit for both hypertriglyceridemia and insulin resistance, highlighting the broad potential of PPARdelta in the treatment of metabolic disease. PPARdelta enhances fatty acid catabolism and energy uncoupling in adipose tissue and muscle, and it suppresses macrophage-derived inflammation. Its combined activities in these and other tissues make it a multifaceted therapeutic target for the metabolic syndrome with the potential to control weight gain, enhance physical endurance, improve insulin sensitivity, and ameliorate atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both overexpression and activation of PPARδ result in increased mitochondrial biogenesis in the absence of an increase in PGC-1α mRNA in skeletal muscle in vivo (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The finding that overexpression of PPARδ in skeletal muscle of transgenic mice does not result in an increase in PGC-1α mRNA led to the conclusion that the increase in mitochondria is mediated directly by PPARδ (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In contrast to the finding in mouse and rat skeletal muscle that PPARδ overexpression or activation does not result in an increase in PGC-1α mRNA, a number of studies have shown that PPARδ induces an increase in PGC-1α gene transcription, with a rapid increase in PGC-1α mRNA, in myotubes (19, 50, 51).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The regulation of PGC-1α expression by PPARδ differs markedly between skeletal muscle in vivo and myotubes in culture.”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Research works printed but not linked: 1
- [77]Lee, C.H., et al. 2006. PPAR delta is a potent insulin sensitizer. Proc. Natl. Acad. Sci. U. S. A. In press.
Cited by
Items 401–500 of 738
Choi, Y., Johnson, J. D., Lee, J.-J., Song, J., Matthews, M. D., Hellerstein, M. K., & McWherter, C. A. (2023) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00158.2023 · Cited by 17
Screening of potential key ferroptosis-related genes in Chronic Obstructive Pulmonary Disease
Cao, Y., Pan, H., Yang, Y., Zhou, J., & Zhang, G. (2023) · International Journal of COPD · doi:10.2147/copd.s422835 · Cited by 17
PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Shafi, S., Gupta, P. K., Khatik, G. L., & Gupta, J. (2019) · Current Drug Targets · doi:10.2174/1389450120666190527115538 · Cited by 17
Bao, X., Fang, Y., You, P., Zhang, S., & Ma, J. (2014) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2014.04.004 · Cited by 17
Diehl, C. J., Barish, G. D., Downes, M., Chou, M.-Y., Heinz, S., Glass, C. K., Evans, R. M., & Witztum, J. L. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0384 · Cited by 17
Self-citationRøst, T. H., Moi, L. L. H., Berge, K., Staels, B., Mellgren, G., & Berge, R. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.06.005 · Cited by 17
Genovese, S., Foreman, J. E., Borland, M. G., Epifano, F., Gonzalez, F. J., Curini, M., & Peters, J. M. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.02.008 · Cited by 17
“2008) and was recently shown to be an excellent target for metabolic syndrome (Barish et al. 2006).”
Chen, C., Ma, C., Zhang, Y., Zeng, Y., Li, Y., & Wang, W. (2014) · Pharmacology · doi:10.1159/000369074 · Cited by 17
Heart Failure in the Diabetic Patient
Bell, D. S. H. (2007) · Cardiology Clinics · doi:10.1016/j.ccl.2007.08.003 · Cited by 17
PPARδ increases expression of the human apolipoprotein A-II gene in human liver cells
Thulin, P., Glinghammar, B., Skogsberg, J., Lundell, K., & Ehrenborg, E. (2008) · International Journal of Molecular Medicine · doi:10.3892/ijmm.21.6.819 · Cited by 17
Duan, Y., Brenig, B., Wu, X., Ren, J., & Huang, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075925 · Cited by 16
Pioglitazone improves insulin sensitivity and reduces weight loss in Walker-256 tumor-bearing rats
Silva, F. D. F., Ortiz‐Silva, M., Galia, W. B. D. S., Cassolla, P., Graciano, M. F. R., Zaia, C. T. B. V., Zaia, D. A. M., Carpinelli, Â. R., da Silva, F. G., & de Souza, H. M. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.12.016 · Cited by 16
Lagu, B. R., Kluge, A. F., Goddeeris, M. M., Tozzo, E., Fredenburg, R. A., Chelur, S., Senaiar, R. S., Jaleel, M., Babu, D. R. K., Tiwari, N. K., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.006 · Cited by 16
Peroxisome Proliferator‐Activated Receptor α Agonists Regulate Cholesterol Ester Transfer Protein
Beyer, T. P., Chen, Y., Porter, R. K., Lu, D., Schmidt, R. J., Mantlo, N. B., Konrad, R. J., & Cao, G. (2008) · Lipids · doi:10.1007/s11745-008-3187-0 · Cited by 16
World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc11-1306 · Cited by 15
Shanaki, M., Hossein‐Nezhad, A., Meshkani, R., Beigy, M., Shirzad, M., Pasalar, P., & Golmohammadi, T. (2016) · PubMed Central · Cited by 15
Kim, D., Ahn, B., Kim, Y. S., Hur, D. Y., Yang, J. W., Park, G. B., Jang, J. E., Lee, E. J., Kwon, M. J., Kim, T. N., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/2376512 · Cited by 15
“PPARs are nuclear hormone receptors that have a variety of regulatory functions in adipogenesis, cellular differentiation, and metabolic homeostasis [19].”
BackgroundPrabhakaran, P., Shanmugarajan, D., Kumar, T. D. A., & Kumar, B. R. P. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1841677 · Cited by 15
“ferentiation, inflammation metabolic disorders and so on (Evans et al., 2004; Barish et al., 2006; Poulsen et al., 2012).”
BackgroundPPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes
Baranova, A. V. (2008) · PPAR Research · doi:10.1155/2008/230893 · Cited by 15
“The physiological effects of activated PPARδ have been studied extensively [22, 102].”
BackgroundLi, W., Ding, Y., Quang, T. H., Nguyen, T. T. N., Sun, Y. N., Yan, X., Yang, S. Y., Choi, C. W., Lee, E. J., Paek, K., et al. (2013) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2013.34.5.1407 · Cited by 15
Palomo, I. F. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.785 · Cited by 15
Chen, Z., Lee, K. S., Chen, L., Wang, L., Niu, H., & Cheng, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064229 · Cited by 15
Saidi, A. O., Akintayo, C. O., Atuma, C. L., Mahmud, H., Sabinari, I. W., Oniyide, A. A., Aturamu, A., Agunbiade, T. B., & Olaniyi, K. S. (2022) · Theriogenology · doi:10.1016/j.theriogenology.2022.02.029 · Cited by 14
Chou, M., Lo, S., Cheng, K., Li, Y.-X., Chen, L., & Cheng, J. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/248320 · Cited by 14
Gu, S., Chen, D., Guo, Z., Zhou, Z.-Y., Hu, X., & Wu, M. (2014) · Endocrine · doi:10.1007/s12020-014-0218-x · Cited by 14
Li, T., Yan, F., Meng, X., Wang, J., Kam, R. K. T., Zeng, X., Liu, Z., Zhou, H., Yang, F., Ren, R., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.011 · Cited by 14
Wei, G., Hao, L., Li, X., Xu, W., Liu, F., Peng, Q., & Lv, S. (2020) · Bioscience Reports · doi:10.1042/bsr20200559 · Cited by 14
Effect of Chronic Valproic Acid Treatment on Hepatic Gene Expression Profile inWfs1Knockout Mouse
Punapart, M., Eltermaa, M., Oflijan, J., Sütt, S., Must, A., Kõks, S., Schalkwyk, L. C., Fernandes, C., Vasar, E., Soomets, U., et al. (2014) · PPAR Research · doi:10.1155/2014/349525 · Cited by 14
Gee, V., Wong, F. S. L., Ramachandran, L., Sethi, G., Kumar, A. P., & Yap, C. W. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9791-6 · Cited by 14
PPARα: its role in the human metabolic syndrome
Azhar, S., & Kelley, G. (2007) · Future Lipidology · doi:10.2217/17460875.2.1.31 · Cited by 14
“More recent evidence suggests that PPARs are also involved in the events connected with inflammation [115–117] and atherosclerosis [118–120], as well as in the regulation of several key components of the metabolic syndrome [121–124].”
BackgroundElbel, E. E., Lavine, J. E., Downes, M., Natta, M. L. V., Yu, R. T., Schwimmer, J. B., Behling, C. A., Brunt, E. M., Tonascia, J., & Evans, R. M. (2018) · Hepatology Communications · doi:10.1002/hep4.1232 · Cited by 14
Indanylacetic acids as PPAR-δ activator insulin sensitizers
Wickens, P. L., Zhang, C., Ma, X., Zhao, Q., Amatruda, J. M., Bullock, W., Burns, M. G., Cantin, L., Chuang, C.-Y., Claus, T. H., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.057 · Cited by 14
Penna, F., Bonelli, G., Baccino, F. M., & Costelli, P. (2009) · Current Medicinal Chemistry · doi:10.2174/092986710790192712 · Cited by 14
“Recent evidence indicates that PPAR/ can promote lipid accumulation by increasing the expression of genes involved in lipid uptake, and by repressing genes involved in lipid metabolism, inflammation, atherosclerosis, obesity and cancer [51].”
Mechanism of Action of Hormones That Act on Nuclear Receptors
Lazar, M. A. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00004-3 · Cited by 14
Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors
Pudakalakatti, S., Titus, M. A., Enriquez, J. S., Ramachandran, S., Zacharias, N. M., Shureiqi, I., Liu, Y., Yao, J. C., Zuo, X., & Bhattacharya, P. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031645 · Cited by 13
Jang, H. S., Kim, H.-J., Kim, D., Park, J., Sun, W.-S., Hwang, S., Oh, K.-B., Jang, W., & Lee, J.-W. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.03.021 · Cited by 13
Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals
Cheng, J., Niu, H., Ku, P., Niu, C., & Lee, K. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s95045 · Cited by 13
Zhang, Y., Gao, T., Hu, S., Lin, B., Yan, D., Xu, Z., Zhang, Z., Mao, Y., Mao, H., Wang, L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143734 · Cited by 13
Kuo, S., Ku, P., Chen, L.-J., Niu, H.-S., & Cheng, J. (2013) · Hormone and Metabolic Research · doi:10.1055/s-0033-1348317 · Cited by 13
Ginseng Is Useful to Enhance Cardiac Contractility in Animals
Lin, J., Cherng, Y., Chen, L., Niu, H., Chang, C. K., & Niu, C. (2014) · BioMed Research International · doi:10.1155/2014/723084 · Cited by 13
The roles ofPPARsin human diseases
Li, J., & Liu, Y. (2018) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2018.1475673 · Cited by 13
Fiévet, C., Fruchart, J.-C., & Staels, B. (2007) · Frontiers in bioscience · doi:10.2741/2376 · Cited by 13
Peroxisome Proliferator-Activated Receptor β/δ Goes Vascular
Bishop‐Bailey, D. (2008) · Circulation Research · doi:10.1161/circresaha.107.170233 · Cited by 13
Xu, X., Chen, Q., Li, S., & Xiong, T. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2024.100035 · Cited by 12
Han, J., Kim, B.-K., Won, J.-Y., Shin, Y., Choi, S.-B., Hwang, I., Kang, J., Lee, H., Koh, S.-J., Lee, J., et al. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.06.002 · Cited by 12
Zhou, Y., Wang, H., Wang, Y., Xu, X., Li, F.-F., Zhou, J., Shan, T., Huang, R., Cai, T., Liu, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.801271 · Cited by 12
The Interaction of FABP with Kapα
Amber-Vitos, O., Kucherenko, N., Nachliel, E., Gutman, M., & Tsfadia, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132138 · Cited by 12
Ying, Y., Burke, R. V., Jeon, C. Y., Chang, S., Chang, P.-Y., Morgenstern, H., Tashkin, D. P., Mao, J., Cozen, W., Mack, T. M., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.06.014 · Cited by 12
Emerging Therapies for Nonalcoholic Fatty Liver Disease
Hameed, B., & Terrault, N. A. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.015 · Cited by 12
Morgado, M., & Carson, D. D. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25622 · Cited by 12
“After binding to PPAR response elements, PPAR heterodimerizes with retinoid X receptor (RXR) and controls expression of genes involved in lipid metabolism, adipogenesis, and inflammation [Barish et al., 2006; Ahmadian et al., 2013].”
BackgroundUpdate on PPAR agonists: The clinical significance of FIELD and PROACTIVE
Robinson, J. G. (2007) · Current Atherosclerosis Reports · doi:10.1007/bf02693930 · Cited by 12
Bouchard‐Mercier, A., Paradis, A.-M., Përusse, L., & Vohl, M. (2012) · Lifestyle Genomics · doi:10.1159/000336511 · Cited by 12
Perreault, M., Will, S., Panza, D., Gareski, T., Harding, K., Kubasiak, D., Jalenak, M., Gartrell, K., Wang, S., Bollag, G. E., et al. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01157.x · Cited by 12
Peroxisome proliferator-activated receptor δ and gastric cancer (Review)
Sung, J. J. �. (2009) · Oncology Reports · doi:10.3892/or_00000456 · Cited by 12
White adipose tissue browning and peroxisome proliferator activated receptors in MASLD
Li, Z., Chu, H., & Yang, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1667037 · Cited by 11
“Activation of PPAR b / d upregulates genes involved in lipoprotein metabolism, thereby reducing plasma cholesterol levels (73, 107), and also exerts anti-in fl ammatory effects in the liver (107, 109).”
Lee, S.-J., Go, G.-Y., Yoo, M., Kim, Y. K., Seo, D. W., Kang, J., & Bae, G. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.012 · Cited by 11
Sun, J. L., Kim, Y. J., Cho, W., Lim, D. S., Gwon, H. J., El‐Aty, A. M. A., Nas, M. A., Jeong, J. H., & Jung, T. W. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150158 · Cited by 11
Lagu, B. R., Kluge, A. F., Fredenburg, R. A., Tozzo, E., Senaiar, R. S., Jaleel, M., Panigrahi, S. K., Tiwari, N. K., Krishnamurthy, N. R., Takahashi, T., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.037 · Cited by 11
Lim, T. K. (2011) · Springer eBooks · doi:10.1007/978-94-007-1764-0_47 · Cited by 11
Quang, T. H., Ngân, N. T. T., Minh, C. V., Kiệm, P. V., Yến, P. H., Tài, B. H., Nhiệm, N. X., Thảo, N. P., Anh, H. L. T., Luyen, B. T. T., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.099 · Cited by 11
Shiochi, H., Ohkura, T., Fujioka, Y., Sumi, K., Yamamoto, N., Nakanishi, R., Matsuzawa, K., Izawa, S., Ohkura, H., Inoue, K., et al. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-113 · Cited by 11
“PPARδ is highly expressed in skeletal muscle, and PPARγ is mainly expressed in adipose tissue, the immune system, and the large intestine [27-29].”
BackgroundWei, L., Mao, J., Lu, J., Gao, J., Zhu, D., Tian, L., Zhao, C., Jia, L., Wang, L., & Fu, R. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000486056 · Cited by 11
Generation and characterization of a humanized PPARδ mouse model
Gross, B. S., Hennuyer, N., Bouchaert, E., Rommens, C., Grillot, D., Mezdour, H., & Staels, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01359.x · Cited by 11
Sadasivuni, M. K., Reddy, B. M., Singh, J. K., Oommen, A. M., Venkategowda, S., Lakshmi, M. N., Yogeshwari, S., Chacko, S. K., Pooja, T. L., Dandu, A., et al. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-83 · Cited by 11
Role of obesity in colorectal carcinogenesis
Hagymási, K., & Tulassay, Z. (2007) · Orvosi Hetilap · doi:10.1556/oh.2007.28244 · Cited by 11
Lack of epithelial PPARγ causes cystic adenomatoid malformations in mouse fetal lung
Kim, J.-H., Yamaori, S., Tanabe, T., Takagi, M., Matsubara, T., Okamoto, M., Kimura, S., & Gonzalez, F. J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.113 · Cited by 10
Wang, Q. A., Cao, H., Su, X., & Liu, W. (2022) · Gene · doi:10.1016/j.gene.2022.146660 · Cited by 10
Ligand‐ and Structure‐Based Drug Design Strategies and PPARδ/α Selectivity
Maltarollo, V. G., & Honório, K. M. (2012) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2012.01424.x · Cited by 10
Lee, J., & Chung, W. Y. (2011) · Endocrinology · doi:10.1210/en.2011-0211 · Cited by 10
“An understanding of PPAR biology could pave the way toward the development of effective therapeutic drugs for treating hypertriglyceridemia and type 2 diabetes mellitus (10).”
BackgroundInvestigating the Role of PPARβ/δ in Retinal Vascular Remodeling Using Pparβ/δ-Deficient Mice
Ho, S. Y., Kwan, Y. P., Qiu, B., Tan, A., Murray, H., Barathi, V. A., Tan, N. S., Cheung, C. M. G., Wong, T. Y., Wahli, W., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124403 · Cited by 10
“Considering the high PPARβ/δ levels in normal mouse retina, an essential role of PPARβ/δ in fatty acid oxidation (FAO) [22,23], and the emerging role of FAO in EC metabolism and angiogenesis [13], we went on exploring the association between retinal Pparβ/δ expression and changes in the body’s metabolic status.”
BackgroundInfluentialWorld Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc11-0840 · Cited by 10
Chin, J., Hong, J. Y., Lee, J., Hwang, H., Ko, H., Choi, H., Hahn, D., Ko, J., Nam, S., Tak, J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.103 · Cited by 10
Look Who's Talking: Nuclear Receptors in the Liver and Gastrointestinal Tract
Downes, M., & Liddle, C. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.02.006 · Cited by 10
“Its activation by fatty acids enhances fatty acid transport and oxidation, improves glucose homeostasis via inhibition of hepatic glucose output, reduces macrophage inflammatory responses, and dramatically increases circulating high-density lipoprotein levels (reviewed in Barish et al., 2006).”
BackgroundTranscriptional regulation of peroxisome proliferator-activated receptors and liver X receptors
Villacorta, L., Garcia-Barrio, M. T., & Chen, Y. E. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0024-5 · Cited by 10
Deshpande, A., Weirauch, L., Baral, T. K., Steier, M., Borlepawar, A., Kumari, M., Kilian, L. S., Richter, K., Hammer, E., Frank, D., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02378-7 · Cited by 9
Ko, S., Cho, B., & Shin, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411883 · Cited by 9
“PPAR γ plays a pivotal role in adipocyte differentiation and the maintenance of insulin sensitivity; its pharmacological activation by thiazolidinediones enhances glucose utilization and contributes to blood glucose control [19].”
Ito, M., Tauscher‐Wisniewski, S., Smulders, R. A., Wojtkowski, T., Yamada, A., Koibuchi, A., Uz, T., Marek, G. J., & Goldwater, R. (2021) · Muscle & Nerve · doi:10.1002/mus.27436 · Cited by 9
“In addition, synthetic PPARδ agonists increase expression of skeletal muscle genes, including those involved in mitochondrial respiration and oxidative metabolism.(23) Given the involvement of PPARδ in mitochondrial bioenergetics, PPARδ modulation could provide intriguing and promising potential for treatment of prima…”
BackgroundShan, J., Kimura, H., Yokoi, S., Kamiyama, K., Imamoto, T., Takeda, I., Kobayashi, M., Mikami, D., Takahashi, N., Kasuno, K., et al. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02039-2 · Cited by 9
Pharmacogenetics of the PPAR Genes and Cardiovascular Disease
Cresci, S. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.11.1581 · Cited by 9
PPARδ Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities
Perreault, M., Erbe, D. V., & Tobin, J. F. (2008) · PPAR Research · doi:10.1155/2008/125387 · Cited by 9
“PPARδ has recently been characterized in rodents and humans and is more widely distributed than its two counterparts with high level of expression in skeletal muscle, heart, kidney, adipose tissue, liver, and macrophages [46].”
BackgroundTherapeutic potential of Mediator complex subunits in metabolic diseases
Ranjan, A., & Ansari, S. A. (2017) · Biochimie · doi:10.1016/j.biochi.2017.10.012 · Cited by 9
Jung, T. W., Lee, H. J., Pyun, D. H., Kim, T. J., Bang, J. S., Song, J.-H., Shin, Y. K., El‐Aty, A. M. A., & Jeong, J. H. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111364 · Cited by 9
Obesity and metabolic syndrome: Future therapeutics based on novel molecular pathways
Gutiérrez-Salmeán, G., Ceballos, G. M., & Ramírez‐Sánchez, I. (2012) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2011.11.002 · Cited by 9
9p21.3 risk locus is associated with first-ever myocardial infarction in an Austrian cohort
Haslacher, H., Perkmann, T., Ratzinger, F., Grimm, G., Exner, M., Keller, A., Schmetterer, K. G., Priemer, C., Endler, G., Wagner, O. F., et al. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000183 · Cited by 9
PPAR δ Activity in Cardiovascular Diseases: A Potential Pharmacological Target
Tesse, A., Andriantsitohaina, R., & Ragot, T. (2009) · PPAR Research · doi:10.1155/2009/745821 · Cited by 9
“PPARδ activators are in development for the treatment of dyslipidemia, obesity and/or insulin resistance in patients with the metabolic syndrome [78].”
BackgroundInvestigational Drugs Targeting HDL-C Metabolism And Reverse Cholesterol Transport
Robinson, J. G., & Davidson, M. H. (2007) · Future Lipidology · doi:10.2217/17460875.2.3.285 · Cited by 9
“The more recently discovered PPARβ/δ has also been found to be a powerful regulator of fatty acid catabolism and energy homeostasis [113].”
BackgroundRival, Y., Puech, L., Taillandier, T., Benéteau, N., Rouquette, A., Lestienne, F., Dupont-Passelaigue, E., Roy, I. L., Patoiseau, J., & Junquero, D. C. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.01.010 · Cited by 9
Sugihara, T. (2025) · Yonago acta medica · doi:10.33160/yam.2025.05.002 · Cited by 8
Osama, H. M., Khadrawy, S. M., El‐Nahass, E., Othman, S. I., & Mohamed, H. M. (2024) · Laboratory Animal Research · doi:10.1186/s42826-024-00204-8 · Cited by 9
“When PPARs are turned on, they heterodimerize with the retinoid X receptor (RXR), which in turn regulates the expression of several genes [21].”
BackgroundL’Abbate, S., Russo, I., & Kusmic, C. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117843 · Cited by 8
Bhurruth-Alcor, Y., Røst, T. H., Jorgensen, M. R., Rajender, Müller, M., Skorve, J., Berge, R. K., & Miller, A. D. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.115 · Cited by 8
Lipid metabolic features of skeletal muscle in pathological and physiological conditions
Son, Y., & Paton, C. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00018-x · Cited by 8
Peroxisome Proliferator–Activated Receptors and The Metabolic Syndrome
Meiliana, A., & Wijaya, A. (2009) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v1i1.79 · Cited by 8
Wang, H., Sun, J., Jia, Z., Yang, T., Xu, L., Zhao, B., Yu, K., & Wang, R. (2015) · PPAR Research · doi:10.1155/2015/480348 · Cited by 8
Ordelheide, A., Heni, M., Thamer, C., Machicao, F. E., Fritsche, A., Stefan, N., Häring, H., & Staiger, H. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02547.x · Cited by 8
Cruz, B. O. D., Cardozo, L., Magliano, D. C., & Stockler‐Pinto, M. B. (2019) · Nutrition Reviews · doi:10.1093/nutrit/nuz058 · Cited by 8
Myćka, G., Musiał, A. D., Stefaniuk‐Szmukier, M., Piórkowska, K., & Ropka‐Molik, K. (2020) · Animals · doi:10.3390/ani10122225 · Cited by 8
Endothelial Progenitor Cells and Angiogenesis Join the PPARty
Biscetti, F., & Pola, R. (2008) · Circulation Research · doi:10.1161/circresaha.108.180224 · Cited by 8
Bartkowiak-Wieczorek, J., Malesza, M., Malesza, I. J., Hadada, T., Winkler-Galicki, J., Grzelak, T., & Mądry, E. (2024) · Nutrients · doi:10.3390/nu16152509 · Cited by 7
“These receptors regulate the metabolism of fats, carbohydrates, and proteins, as well as cell division and immune processes, such as the intensification of inflammation [47].”
Background
Metadata
- Authors
- Barish, G. D.
- Affiliations
- Salk Institute for Biological Studies (US)
- Corresponding author
- Barish, G. D.
- ORCID
- Barish, G. D.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-03-01
- Volume
- 116
- Issue
- 3
- Pages
- 590-597
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1386117
- OpenAlex
- W1987601141
- Cited by
- 641
- References
- 100
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 16 · 2023: 7 · 2022: 12 · 2021: 9 · 2020: 23 · 2019: 15 · 2018: 24 · 2017: 26 · 2016: 28 · 2015: 29 · 2014: 31 · 2013: 39 · 2012: 46
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- March of Dimes Foundation
- Larry L. Hillblom Foundation
- National Institutes of Health (U19DK62434)
- University of California, San Diego
- National Heart, Lung, and Blood Institute (P50HL56989, P50HL056989)
- National Institute of Diabetes and Digestive and Kidney Diseases (U19 DK-62434, U19DK062434, F32DK071478)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- PPARδ, PPARα, PPARγ, metabolic syndrome, insulin resistance, hypertriglyceridemia, obesity, fatty acid degradation, adipose tissue, skeletal muscle, macrophage inflammation, atherosclerosis, nuclear receptors, weight gain, physical endurance
- MeSH terms
- Animals, Humans, Myocardium, Muscle, Skeletal, Metabolic Syndrome, PPAR delta, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.